Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741948 | 0.95 | UTS2R (0.43) | METKDRMAPK8MAPK9MAPK10 | |
| SCHEMBL1741966 | 0.84 | MAPT (0.45) | METKDRLRRK2AXL | |
| SCHEMBL2838684 | 0.83 | UTS2R (0.48) | METKDRLRRK2AXLUTS2R | |
| SCHEMBL1741332 | 0.82 | KDM4E (0.48) | METKDRLRRK2AXL | |
| SCHEMBL1741954 | 0.82 | MET (0.43) | METKDRLRRK2AXL | |
| SCHEMBL1742662 | 0.81 | STK4 (0.47) | METKDRLRRK2AXLUTS2R | |
| SCHEMBL1742647 | 0.80 | MET (0.55) | METKDRAXL | |
| SCHEMBL1741248 | 0.80 | MET (0.42) | METKDRAXL | |
| SCHEMBL1743562 | 0.78 | MET (0.45) | METKDRLRRK2AXLUTS2R | |
| SCHEMBL1742654 | 0.78 | MET (0.47) | METKDRMAPK8LRRK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563579-B2 | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2013-10-22 | — | — | US | claimed |
| EP-2387575-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2387575-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2011-11-23 | — | — | EP | claimed |
| US-D647030-S1 | Automobile tire tread | THE YOKOHAMA RUBBER CO., LTD (JP) | 2011-10-18 | — | — | US | claimed |
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ALPHARMAGEN LLC | 2010-07-29 | — | — | US | claimed |
| WO-2010083444-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL, LLC (US) | 2010-07-22 | — | — | WO | claimed |
| US-8975407-B2 | α7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140194462-A1 | Alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ANVYL LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8563579-B2 | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2387575-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2387575-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-D647030-S1 | Automobile tire tread | THE YOKOHAMA RUBBER CO., LTD (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ALPHARMAGEN LLC | 2010-07-29 | — | — | US | disclosed |
| WO-2010083444-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL, LLC (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNG | MET 4323/4885KDR 4098/4885MAPK8 1265/4885 |
| US-20140194462-A1 | Alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNG | MET 4323/4885KDR 4098/4885MAPK8 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.